Trial
NCT02920424
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus
Phase IWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Lupus Erythematosus, Systemic
Intervention
JNJ-56022473
Why stopped
The decision is based on a change in the benefit risk assessment of this drug for the lupus population targeted in this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-27